prikaz prve stranice dokumenta Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
  Preuzmi
PDF 713.07 KB
Znanstveni rad - Izvorni znanstveni rad
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
Multiple Sclerosis Journal, 25 (2019), 9; 1273-1288. https://doi.org/10.1177/1352458519841829
Phelps, Richard; Winston, Jonathan A; Wynn, Daniel; Habek, Mario; Hartung, Hans-Peter; Havrdová, Eva Kubala; Markowitz, Glen S; Margolin, David H; Rodriguez, Claudio E; Baker, Darren P; Coles, Alasdair J

Citirajte ovaj rad

Phelps, R., Winston, J. A., Wynn, D., Habek, M., Hartung, H. P., Havrdová, E. K. ... Coles, A. J. (2019). Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 25. (9), 1273-1288. doi: 10.1177/1352458519841829

Phelps, Richard, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal, vol. 25, br. 9, 2019, str. 1273-1288. https://doi.org/10.1177/1352458519841829

Phelps, Richard, Jonathan A Winston, Daniel Wynn, Mario Habek, Hans Peter Hartung, Eva Kubala Havrdová, Glen S Markowitz, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal 25, br. 9 (2019): 1273-1288. https://doi.org/10.1177/1352458519841829

Phelps, R., et al. (2019) 'Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis', Multiple Sclerosis Journal, 25(9), str. 1273-1288. doi: 10.1177/1352458519841829

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, i sur.. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal [Internet]. 08.2019. [pristupljeno 25.10.2024.];25(9):1273-1288. doi: 10.1177/1352458519841829

R. Phelps, et al., "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis", Multiple Sclerosis Journal, vol. 25, br. 9, str. 1273-1288, Kolovoz 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:942822. [Citirano: 25.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:942822
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
AutorRichard Phelps
AutorJonathan A Winston
AutorDaniel Wynn
AutorMario Habek
AutorHans-Peter Hartung
AutorEva Kubala Havrdová
AutorGlen S Markowitz
AutorDavid H Margolin
AutorClaudio E Rodriguez
AutorDarren P Baker
AutorAlasdair J Coles
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Background: Autoimmune disorders including nephropathies have been reported more frequently in alemtuzumab-treated multiple sclerosis (MS) patients than in the general population. ----- Objective: Describe instances of autoimmune nephropathy in alemtuzumab-treated MS patients. ----- Methods: Cases were identified from safety monitoring within the alemtuzumab relapsing-remitting multiple sclerosis (RRMS) clinical development program (CDP) or post-marketing, or following off-label use. ----- Results: As of 16 June 2017, 16 autoimmune nephropathies have occurred following alemtuzumab treatment for MS. The incidence of autoimmune nephropathies was 0.34% within the CDP (5/1485 patients). The five CDP cases (one of anti-glomerular basement membrane (anti-GBM) disease, two of membranous glomerulonephropathy, and two of serum anti-GBM antibody without typical anti-GBM disease) were identified early, responded to conventional therapy (where needed), and had favorable outcomes. Three of 11 cases outside the CDP occurred following off-label alemtuzumab use prior to approval for RRMS and were all anti-GBM disease. Diagnosis was delayed in one of these three cases and another did not receive appropriate treatment; all three cases resulted in end-stage renal failure. All anti-GBM disease cases with documented urinalysis demonstrated prior microscopic hematuria. ----- Conclusion: Close monitoring of alemtuzumab-treated MS patients facilitates diagnosis and treatment early in the nephropathy course when preservation of renal function is more likely.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMultiple Sclerosis Journal
Brojčani podacivol. 25, br. 9, str. 1273-1288
p-ISSN1352-4585
DOIhttps://doi.org/10.1177/1352458519841829
URN:NBNurn:nbn:hr:105:942822
Datum objave publikacije2019-08
URL dokumentahttp://doi.org/10.1177/1352458519841829
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 10:34:55